BioVision by Mirthulaa

 Introduction Vaccination has historically relied on injectable routes, cold-chain storage, and trained personnel, posing challenges in global immunization coverage. Recent biotechnological innovations are shifting the paradigm toward edible vaccines and functional foods. One promising avenue involves using genetically engineered yeast, specifically Saccharomyces cerevisiae, as a vaccine production platform, and delivering these antigens via fermented or processed foods. This convergence of synthetic biology, industrial fermentation, and nutraceuticals offers a potent, scalable, and needle-free alternative to traditional vaccines. Why Saccharomyces cerevisiae? Yeast has long been a workhorse in biotechnology due to: GRAS (Generally Recognized as Safe) status by FDA Extensive history in bread, beer, and wine production Established genetic manipulation tools Ability to post-translationally modify proteins, unlike bacteria Saccharomyces cerevisiae has been successfully used to express...

Introduction Imagine a city where streetlights are replaced with glowing trees. This isn’t science fiction anymore—it's real science. Synthetic biology has enabled researchers to genetically engineer plants that emit light using genes borrowed from bioluminescent organisms like fireflies and certain fungi. While this technology is still in early development, it holds tremendous promise for sustainable urban lighting. The Science Behind the Glow The principle is simple: take the genes responsible for bioluminescence (like luciferase and luciferin production) and insert them into plants using recombinant DNA technology. These genes catalyze chemical reactions that emit visible light. Notable Techniques: Gene Transfer: Bioluminescent genes are inserted into Arabidopsis, Nicotiana (tobacco), or other host plants. Promoter Engineering: Modified promoters enhance expression and brightness. Fungal and Bacterial Pathways: Some studies incorporate fungal enzymes to allow continuous light em...

 In the fight against drug-resistant pathogens, science is reaching into the distant past. A fascinating and rare frontier in medicinal biotechnology is the concept of molecular de-extinction—the process of retrieving and synthesizing ancient proteins from extinct species to discover new therapeutic molecules. Unearthing Ancient Antimicrobial Peptides (AMPs) A research group from the University of Pennsylvania’s Machine Biology Lab recently employed deep learning algorithms to search for antimicrobial peptides (AMPs) in the proteomes of extinct species like Neanderthals, woolly mammoths, and Denisovans. Using a custom AI model called panCleave, they simulated proteolytic cleavage and identified short peptides with potential antibacterial activity. Among their top discoveries: Mammuthusin-2 (from woolly mammoth): Active against multidrug-resistant Acinetobacter baumannii Elephasin-2 (from extinct straight-tusked elephant): Effective in preclinical models These AMPs were chemically s...

Introduction Mosquitoes are infamous for their role in spreading deadly diseases such as malaria, dengue, and Zika. But what if these tiny insects could be repurposed to deliver life-saving medicines instead? Scientists are exploring the potential of using mosquitoes as biological drug delivery systems, turning nature’s most notorious vector into a tool for good. How Could Mosquitoes Be Used for Drug Delivery? Genetically Engineered Mosquitoes for Vaccination Instead of carrying pathogens, genetically modified mosquitoes could be designed to produce and inject therapeutic molecules, such as vaccines or antibodies, when they bite a human. Research has shown that mosquito salivary glands can be engineered to secrete bioactive proteins. 📌 Potential Application: Scientists are investigating whether mosquito saliva can be modified to carry vaccines for diseases like malaria and dengue, essentially transforming each bite into a mini-injection. Mosquito-Associated Microbes as Drug Carriers M...

Introduction Cancer research has undergone a paradigm shift with the emergence of in vitro tumor models that closely mimic in vivo conditions. Among these, Tumoroid-on-a-Chip technology, Organoid-Tumoroid Hybrid Models, Tumoroid-Derived Extracellular Vesicles (EVs), and Integration with Immuno-Oncology Models are revolutionizing cancer biology, drug development, and personalized medicine. This blog explores these cutting-edge technologies, their applications, and their potential to transform cancer therapy. 1. Tumoroid-on-a-Chip Technology: Mimicking the Tumor Microenvironment (TME) 1.1 What is Tumoroid-on-a-Chip? Tumoroid-on-a-Chip technology integrates microfluidics with 3D tumor cultures, allowing precise control over biochemical and biomechanical signals within the tumor microenvironment (TME). These devices simulate the dynamic interactions between cancer cells, stromal cells, and blood vessels, overcoming limitations of traditional 2D cultures and animal models. 1.2 Fabrication a...